Shire

Amicus to file Fabry drug after FDA changes mind

July 12, 2017

Regulator drops demand for further phase 3 trial.

Amicus to file Fabry drug after FDA changes mind

https://pharmaphorum.com/news/amicus-therapeutics-fabry-drug-us-fda-changes-mind/

Shire injunction blocks Roche’s ‘misleading’ statements on haemophilia drugs

July 10, 2017

Shire alleges trial info “unlawfully disparages” its product.

Shire injunction blocks Roche’s ‘misleading’ statements on haemophilia drugs

https://pharmaphorum.com/news/shire/

Data stacking up for Roche haemophilia A drug

June 26, 2017

But analysts concerned over safety.

Data stacking up for Roche haemophilia A drug

https://pharmaphorum.com/news/data-stacks-roche-haemophilia-drug/

Shire long-acting ADHD drug finally approved

June 21, 2017

Mydadis approval ends decade-long saga with FDA.

Shire long-acting ADHD drug finally approved

https://pharmaphorum.com/news/shire-long-acting-adhd-drug-finally-approved/

Shire plans filing for HAE drug after phase 3 success

May 19, 2017

Lanadelumab could revolutionise treatment of swelling disease.

Shire plans filing for HAE drug after phase 3 success

https://pharmaphorum.com/news/shire-plans-filing-hae-drug-phase-3-success/

CEO Meek looks to boost Ipsen with drug acquisitions

May 11, 2017

Could French biotech snap up remaining rights to pancreatic cancer drug?

CEO Meek looks to boost Ipsen with drug acquisitions

https://pharmaphorum.com/news/ipsen-looks-boost-rd-acquisitions/

Novartis takes option on NASH drug from Conatus

May 4, 2017

Swiss pharma takes option on FXR agonist emricasan.

Novartis takes option on NASH drug from Conatus

https://pharmaphorum.com/news/novartis-takes-option-nash/

PatientsLikeMe and Shire to co-develop rare disease patient network

April 11, 2017

Data from the new platform will help inform rare disease drug development.

PatientsLikeMe and Shire to co-develop rare disease patient network

https://pharmaphorum.com/news/patientslikeme-shire-co-develop-rare-disease-patient-network/

Novartis takes aim at Shire and Allergan with dry-eye drug

April 7, 2017

Swiss company takes option on Lubris’ ECF843.

Novartis takes aim at Shire and Allergan with dry-eye drug

https://pharmaphorum.com/news/novartis-takes-aim-shire-allergan-dry-eye-drug/

1 2 3 4 5

CONTINUE TO SITE >

Close in 10 seconds

Pharmaphorum.com

Trending

Shire

Amicus to file Fabry drug after FDA changes mind

Shire injunction blocks Roche’s ‘misleading’ statements on haemophilia drugs

Data stacking up for Roche haemophilia A drug

Shire long-acting ADHD drug finally approved

Shire plans filing for HAE drug after phase 3 success

CEO Meek looks to boost Ipsen with drug acquisitions

Novartis takes option on NASH drug from Conatus

Novartis takes aim at Shire and Allergan with dry-eye drug

Inhalation and Respiratory Drug Products Summit

THET Annual Conference 2017

Clinical Trial Supply East Coast 2017

Livongo’s diabetes solution impresses in latest study

Vifor’s hyperkalaemia drug Veltassa approved in Europe

New 3-year data supports Kite ‘cure’ hopes for CAR-T

Daiichi Sankyo anticoagulant gains EU label boost

Teva’s Cinqaero to challenge Nucala after clearing NICE

The most notable digital health trends of 2017 so far

Europe has untapped medical innovation – but needs high speed connections to make it work

Healthcare’s hype cycle: which technologies will stay the course?

Looking back, looking forward – Janssen’s 60 years on the psychiatry horizon

What HCPs say about Roche’s breast cancer drug

Search

Advanced Search

Trending

Shire